|
Market Closed -
Nasdaq
09:30:00 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 0.1052 USD | -10.09% |
|
-34.25% | -87.62% |
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-13 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
Company Valuation: CASI Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 365.6 | 111.8 | 24.35 | 95.38 | 43.84 | 17.47 |
| Change | - | -69.41% | -78.22% | 291.63% | -54.03% | -60.16% |
| Enterprise Value (EV) 1 | 302.5 | 65.43 | -25.64 | 85.85 | 49.89 | 39.32 |
| Change | - | -78.37% | -139.18% | 434.86% | -41.88% | -21.19% |
| P/E | -6.75x | -2.96x | -0.59x | -3.55x | -1.11x | -0.33x |
| PBR | 4.48x | 1.32x | 0.54x | 3.96x | 23.7x | -0.47x |
| PEG | - | 0.1x | -0.1x | 0.1x | -0x | -0.26x |
| Capitalization / Revenue | 24.1x | 3.71x | 0.56x | 2.82x | 1.54x | 0.84x |
| EV / Revenue | 20x | 2.17x | -0.59x | 2.53x | 1.75x | 1.9x |
| EV / EBITDA | -9.65x | -1.96x | 1.07x | -3.99x | -1.35x | -0.95x |
| EV / EBIT | -9.08x | -1.85x | 0.97x | -3.4x | -1.27x | -0.92x |
| EV / FCF | -11.7x | -2.39x | 1.47x | -6.26x | -3.28x | -60.4x |
| FCF Yield | -8.55% | -41.8% | 67.9% | -16% | -30.5% | -1.66% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -4.372 | -2.7 | -3.01 | -2.018 | -2.56 | -2.592 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 15.14 | 30.17 | 43.11 | 33.88 | 28.54 | 20.71 |
| EBITDA 1 | -31.35 | -33.47 | -24.07 | -21.54 | -36.88 | -41.59 |
| EBIT 1 | -33.31 | -35.28 | -26.49 | -25.28 | -39.21 | -42.85 |
| Net income 1 | -48.29 | -36.65 | -41.01 | -26.94 | -39.26 | -48.06 |
| Net Debt 1 | -63.18 | -46.41 | -49.99 | -9.53 | 6.05 | 21.85 |
| Reference price 2 | 29.5000 | 8.0000 | 1.7900 | 7.1600 | 2.8300 | 0.8500 |
| Nbr of stocks (in thousands) | 12,394 | 13,980 | 13,606 | 13,322 | 15,493 | 20,548 |
| Announcement Date | 3/30/21 | 3/28/22 | 4/26/23 | 3/28/24 | 3/31/25 | 5/15/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.46x | 11.79x | 23.8x | 0.61% | 1,019B | |
| 28.13x | 6.24x | 17.86x | 2.11% | 610B | |
| 33.64x | 7.86x | 16.24x | 2.61% | 470B | |
| 101.52x | 5.7x | 24.22x | 2.45% | 344B | |
| 18.95x | 4.61x | 11.45x | 2.87% | 336B | |
| 19.74x | 5.16x | 12.75x | 3.1% | 266B | |
| 19.84x | 4.13x | 11.77x | 2.15% | 241B | |
| 25.45x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.74x | 6.39x | 24.95x | 2.28% | 179B | |
| Average | 26.22x | 6.50x | 17.21x | 2.3% | 409.2B | |
| Weighted average by Cap. | 31.25x | 7.60x | 18.53x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CASIF Stock
- CASI Stock
- Valuation CASI Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
